Patents for A61P 35 - Antineoplastic agents (221,099)
07/2012
07/25/2012CN101805383B Strictosidine lactam derivatives and preparation method and use thereof
07/25/2012CN101768614B Method for efficiently extracting polysaccharide and polyphenol from agaricus blazei
07/25/2012CN101766599B Drug combination preparation containing qidimacrin or medicinal composites thereof
07/25/2012CN101748122B Disturbing molecule for inhibiting expression of TM4SF4 and application thereof
07/25/2012CN101747411B Aminoacyl tryptophyl tryptophan tripeptide benzyl ester as well as preparation method and application thereof
07/25/2012CN101747326B 18-macrolide epothilone compound and application thereof
07/25/2012CN101732723B Polyethylene glycol-poly(lactic-co-glycolic acid)-polylysine nano-delivery system, preparation method and application thereof
07/25/2012CN101724007B Oleanolic acid derivatives and application thereof serving as alpha-glucosidase inhibitor
07/25/2012CN101716256B Preparation used for strengthening immunity
07/25/2012CN101687934B Pegylated erythropoietin conjugate and preparation method and uses thereof
07/25/2012CN101678037B Combined use of cholestanol derivative
07/25/2012CN101675994B Therapy vaccine preparation
07/25/2012CN101648022B Nanometer microsphere or hollow sphere of casein or casein-polyacrylic acid compound and preparation method and application thereof
07/25/2012CN101633638B Class I histone deacetylase inhibitor and application thereof
07/25/2012CN101628912B Anti-tumor compound containing triazole heterocyclic structure and application thereof
07/25/2012CN101622342B Cancerous disease modifying antibodies
07/25/2012CN101612146B Oxaliplatin medicament composition, preparation method thereof
07/25/2012CN101554392B Medical prescription of new medicine ester glycosides capsule for treating tumour and preparation technique thereof
07/25/2012CN101525289B Method for separating purified ginkgoic acid with anion exchanger
07/25/2012CN101506239B Antihuman alpha9 integrin antibody and use of the same
07/25/2012CN101502508B Application of 5-oxo-4-alkenylene-pyrazole derivative in preparing anti-tumor medicament
07/25/2012CN101497567B Preparation of caffeic acid 3,4-dihydroxyphenyl ethyl ester and its derivative phenyl acrylic acid phenyl alkyl ester compound
07/25/2012CN101496884B Capsule for treating gastric precancerous lesion
07/25/2012CN101492715B siRNA for suppressing human CSAG1 gene expression through RNA interference and uses of siRNA
07/25/2012CN101492710B Uses of ZCCHC13 gene
07/25/2012CN101434524B 4-(4-hydroxy-3-methoxybenzene methylene) curcumin, preparation thereof and use in preparing anti-cancer medicament
07/25/2012CN101337001B Solanum xanthocarpum extract, preparation method and use thereof
07/25/2012CN101094844B Chroman derivatives, medicaments and use in therapy
07/24/2012US8227634 Imaging agents and methods of imaging NAALADase or PSMA
07/24/2012US8227585 Human mini-antibody cytotoxic for tumor cells which express the ERBB2 receptor
07/24/2012US8227515 Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments
07/24/2012US8227512 Pharmaceutical composition containing daurinol for the prevention and treatment of cancers
07/24/2012US8227440 Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
07/24/2012US8227413 Compositions and methods for inducing angiogenesis
07/24/2012US8227402 Peptide facilitating the entry of a linked molecule into a mammalian cancer cell; copper binding protein; inhibit the development of premalignant lesions in mammalian tissue
07/24/2012US8227200 Methods for identifying kremen polypeptide binding partners
07/24/2012US8226950 Recombinant anti-VLA4 antibody molecules
07/24/2012CA2686378C Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
07/24/2012CA2486252C Methods for screening for agents that modulate hepatocellular carcinoma development
07/24/2012CA2476065C Inhibitors of histone deacetylase
07/24/2012CA2471822C Cell-specific herpes simplex virus expression/replication vector comprising icp4 and human calponin gene promoter
07/24/2012CA2410887C Compounds for targeting endothelial cells, compositions containing the same and methods for their use
07/24/2012CA2342289C Treatment of cervical cancer
07/19/2012WO2012097371A2 Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
07/19/2012WO2012097333A2 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
07/19/2012WO2012097222A1 High drug load tablet formulation of brivanib alaninate
07/19/2012WO2012097196A1 Pyrazolopyrimidine derivatives and uses as anticancer agents
07/19/2012WO2012097173A2 Substituted benzoazepines as toll-like receptor modulators
07/19/2012WO2012097133A2 Compounds and methods for inducing apoptosis in cancer cells using a bh3 alpha-helical mimetic
07/19/2012WO2012097121A2 Specific nnos inhibitors for the therapy and prevention of human melanoma
07/19/2012WO2012097057A2 Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
07/19/2012WO2012097054A1 Methods and compositions for treating cancer and related methods
07/19/2012WO2012097049A2 Dna repair enzyme inhibitor nanoparticles and uses thereof
07/19/2012WO2012097039A1 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
07/19/2012WO2012096919A1 Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
07/19/2012WO2012096832A2 Hdac inhibiting derivatives of camptothecin
07/19/2012WO2012096722A1 Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
07/19/2012WO2012096718A2 Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
07/19/2012WO2012096573A1 Mirna for treating diseases and conditions associated with neo-angiogenesis
07/19/2012WO2012096545A2 Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
07/19/2012WO2012095849A1 Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
07/19/2012WO2012095836A1 Anti-angiogenic compound
07/19/2012WO2012095820A1 Use of simalikalactone e as an anticancer agent
07/19/2012WO2012095804A1 Means for reducing or eradicating the tumour capacity of cancer stem cells and/or metastatic stem cells.
07/19/2012WO2012095789A1 Pharmaceutical composition for treating cancer
07/19/2012WO2012095607A1 Preventive effect of citrulline on the spontaneous development of tumors
07/19/2012WO2012095509A1 Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases
07/19/2012WO2012095505A1 Anticancer therapy with dual aurora kinase / mek inhibitors
07/19/2012WO2012095433A1 Compositions comprising 2-chloro-n- (4 - chloro - pyridin- 2 - yl - phenyl) - 4 -methanesulfonyl - benzamide and 2, 2 -dimethyl -n- ( (s) - 6-0x0-6, 7 - dihydro - 5h - dibenzo [b, d] azepin-7 -yl) -n' - (2,2,3,3,3- pentafluoro - propyl) malonamide
07/19/2012WO2012095142A1 5-([1,2,3]triazole-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives
07/19/2012WO2012094966A1 3-aryl-6-aryl-[1,2,4]triazolo[4,3-b]pyridazine as cell proliferation inhibiting agent and use thereof
07/19/2012WO2012094788A1 Paraterphenyl derivative and use thereof for preparing antitumor medicaments
07/19/2012WO2012065106A3 Compounds and related methods for manipulating parp-1-dependent cell death
07/19/2012WO2012064792A3 Protein complexes for antigen binding and methods of use
07/19/2012WO2012064159A3 Anticancer composition
07/19/2012WO2012064130A3 Colon-targeted celecoxib precursor compound and pharmaceutical composition containing the compound as an active ingredient for treating or preventing colonic diseases
07/19/2012WO2012064087A3 Pharmaceutical composition including polymer microsphere containing anastrozole as active ingredient
07/19/2012WO2012059857A3 Pan-her antibody composition
07/19/2012WO2012058529A3 Metalloenzyme inhibitor compounds
07/19/2012WO2012058418A3 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
07/19/2012WO2012051247A3 Egfr-based peptides
07/19/2012WO2012045090A3 Therapeutic use of a tlr agonist and combination therapy
07/19/2012WO2012036412A3 Peptide having a vascularization-suppressing activity and a use therefor
07/19/2012WO2012034055A3 Compounds as c-met kinase inhibitors
07/19/2012WO2012033901A3 Somatostatin receptor-based cancer therapy
07/19/2012WO2012031118A3 Cell permeable inhibitors of anaphase promoting complex
07/19/2012WO2012012305A3 Combination therapy using a ruthenium complex
07/19/2012WO2012004631A3 Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
07/19/2012WO2011159917A3 Growth hormone secretatogue receptor antagonists and uses thereof
07/19/2012WO2011130434A9 Antibodies that bind human cd27 and uses thereof
07/19/2012US20120184620 Antioxidant composition
07/19/2012US20120184611 Selenoquinone-derived active organometallic complexes, methods for synthesizing same, and uses thereof
07/19/2012US20120184604 Composition for the prevention or treatment of bone diseases comprising colforsin daropate
07/19/2012US20120184597 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
07/19/2012US20120184592 Alkyl indole-3-carbinol-derived antitumor agents
07/19/2012US20120184590 Formulations of indole-3-carbinol derived antitumor agents with increased oral bioavailability
07/19/2012US20120184583 Modulators of atp-binding cassette transporters
07/19/2012US20120184580 Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
07/19/2012US20120184578 Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
07/19/2012US20120184577 PI3 KINASE/mTOR DUAL INHIBITOR